{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:18:47Z","timestamp":1792671527647,"version":"4.5.0"},"reference-count":65,"publisher":"Tech Science Press","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2025.071708","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T17:19:36Z","timestamp":1759425576000},"page":"3375-3385","source":"Crossref","is-referenced-by-count":28,"title":["CD47-Targeted Therapy in Cancer Immunotherapy: At a Crossroads of Promise and Challenge"],"prefix":"10.32604","volume":"33","author":[{"given":"Xuejun","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.32604\/or.2023.042383","article-title":"Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy","volume":"32","author":"Chen","year":"2023","journal-title":"Oncol Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jare.2023.10.009","article-title":"Deciphering the role of CD47 in cancer immunotherapy","volume":"63","author":"Liu","year":"2024","journal-title":"J Adv Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"189294","DOI":"10.1016\/j.bbcan.2025.189294","article-title":"CD47 as a potent target in cancer immunotherapy: a review","volume":"1880","author":"Ahvati","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"109546","DOI":"10.1016\/j.isci.2024.109546","article-title":"Disruption of CD47-SIRPalpha signaling restores inflammatory function in tumor-associated myeloid-derived suppressor cells","volume":"27","author":"Zimarino","year":"2024","journal-title":"iScience"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1612234","DOI":"10.3389\/fimmu.2025.1612234","article-title":"Deciphering the role of signal regulatory protein alpha in immunotherapy for solid tumors","volume":"16","author":"Zhou","year":"2025","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","article-title":"Harnessing innate immune pathways for therapeutic advancement in cancer","volume":"9","author":"Hu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"100070","DOI":"10.1016\/j.iotech.2022.100070","article-title":"CD47-SIRPalpha-targeted therapeutics: status and prospects","volume":"13","author":"Maute","year":"2022","journal-title":"Immunooncol Technol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.36401\/JIPO-21-X2","article-title":"Targeting CD47\/SIRPalpha in acute myeloid leukemia and myelodysplastic syndrome: preclinical and clinical developments of magrolimab","volume":"4","author":"Haddad","year":"2021","journal-title":"J Immunother Precis Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/imm.13498","article-title":"Advances in the study of CD47-based bispecific antibody in cancer immunotherapy","volume":"167","author":"Zhang","year":"2022","journal-title":"Immunology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00432-021-03815-z","article-title":"Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective","volume":"148","author":"Chen","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1348852","DOI":"10.3389\/fimmu.2024.1348852","article-title":"Opportunities and challenges for anti-CD47 antibodies in hematological malignancies","volume":"15","author":"Xu","year":"2024","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40364-023-00456-x","article-title":"The landscape overview of CD47-based immunotherapy for hematological malignancies","volume":"11","author":"Yang","year":"2023","journal-title":"Biomark Res"},{"key":"ref14","first-page":"100498","article-title":"Brief report: high levels of CD47 expression in thymic epithelial tumors","volume":"4","author":"Sun","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41698-023-00418-4","article-title":"Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition","volume":"7","author":"Al-Sudani","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1038\/s41467-021-25475-w","article-title":"Structure of the human marker of self 5-transmembrane receptor CD47","volume":"12","author":"Fenalti","year":"2021","journal-title":"Nat Commun"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"101450","DOI":"10.1016\/j.xcrm.2024.101450","article-title":"Expression of a mutant CD47 protects against phagocytosis without inducing cell death or inhibiting angiogenesis","volume":"5","author":"Xu","year":"2024","journal-title":"Cell Rep Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12974-025-03414-6","article-title":"SIRPalpha modulates microglial efferocytosis and neuroinflammation following experimental subarachnoid hemorrhage via the SHP1\/STAT6 axis","volume":"22","author":"Zhang","year":"2025","journal-title":"J Neuroinflammation"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.devcel.2024.01.020","article-title":"Redistribution of the glycocalyx exposes phagocytic determinants on apoptotic cells","volume":"59","author":"Le","year":"2024","journal-title":"Dev Cell"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"757480","DOI":"10.3389\/fimmu.2022.757480","article-title":"CD47 as a promising therapeutic target in oncology","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.ccell.2023.10.007","article-title":"The antitumor activities of anti-CD47 antibodies require Fc-FcgammaR interactions","volume":"41","author":"Osorio","year":"2023","journal-title":"Cancer Cell"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00262-025-04032-0","article-title":"Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy","volume":"74","author":"Reischer","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"130448","DOI":"10.1016\/j.bbagen.2023.130448","article-title":"Serum immunoglobulin and the threshold of Fc receptor-mediated immune activation","volume":"1867","author":"Bauer-Smith","year":"2023","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin Cancer Res"},{"key":"ref25","first-page":"100268","article-title":"CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies","volume":"16","author":"Sun","year":"2021","journal-title":"Leuk Res Rep"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"111478","DOI":"10.1016\/j.isci.2024.111478","article-title":"Translating CD47-targeted therapy in gastrointestinal cancers: insights from preclinical to clinical studies","volume":"27","author":"Chen","year":"2024","journal-title":"iScience"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","article-title":"Engineered CD47 protects T cells for enhanced antitumour immunity","volume":"630","author":"Yamada-Hunter","year":"2024","journal-title":"Nature"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.3390\/ijms26115394","article-title":"Emerging immunotherapy targets in early drug development","volume":"26","author":"Morchon-Araujo","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"27957","DOI":"10.1021\/acsnano.5c10591","article-title":"Focused acoustic vortex-activated dual-stimuli nanoplatform synergizes with checkpoint blockade to enhance macrophage phagocytosis and antitumor immunity","volume":"19","author":"Li","year":"2025","journal-title":"ACS Nano"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e70014","DOI":"10.1002\/cti2.70014","article-title":"Dual CD47 and PD-L1 blockade elicits anti-tumor immunity by intratumoral CD8(+) T cells","volume":"13","author":"Christo","year":"2024","journal-title":"Clin Transl Immunol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"9718","DOI":"10.1038\/s41467-024-54129-w","article-title":"Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPgamma-derived CD47 blocker","volume":"15","author":"Martins","year":"2024","journal-title":"Nat Commun"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.clml.2025.01.021","article-title":"SOHO state of the art updates and next questions | novel immunotherapy combinations for the treatment of indolent B-cell lymphoma","volume":"25","author":"Zhuang","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.3390\/ijms26125838","article-title":"Bispecific antibodies in solid tumors: advances and challenges","volume":"26","author":"Shan","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12951-020-0571-2","article-title":"Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential","volume":"18","author":"Ma","year":"2020","journal-title":"J Nanobiotechnol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1548588","DOI":"10.3389\/fbioe.2025.1548588","article-title":"Nanotechnology in cancer treatment: revolutionizing strategies against drug resistance","volume":"13","author":"Sabir","year":"2025","journal-title":"Front Bioeng Biotechnol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1016\/j.ymthe.2025.03.018","article-title":"CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery","volume":"33","author":"Papp","year":"2025","journal-title":"Mol Ther"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"712","DOI":"10.4049\/jimmunol.2001019","article-title":"Novel SIRPalpha antibodies that induce single-agent phagocytosis of tumor cells while preserving T cells","volume":"206","author":"Andrejeva","year":"2021","journal-title":"J Immunol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40364-022-00373-5","article-title":"Targeting CD47\/SIRPalpha as a therapeutic strategy, where we are and where we are headed","volume":"10","author":"Qu","year":"2022","journal-title":"Biomark Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e1584","DOI":"10.1002\/ctm2.1584","article-title":"Tolerating CD47","volume":"14","author":"Isenberg","year":"2024","journal-title":"Clin Transl Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"e006567","DOI":"10.1136\/jitc-2022-006567","article-title":"BYON4228 is a pan-allelic antagonistic SIRPalpha antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPgamma on T cells","volume":"11","author":"van Helden","year":"2023","journal-title":"J Immunother Cancer"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"e010565","DOI":"10.1136\/jitc-2024-010565","article-title":"First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer","volume":"13","author":"Lakhani","year":"2025","journal-title":"J Immunother Cancer"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.3390\/cancers15215229","article-title":"CD47: the next frontier in immune checkpoint blockade for non-small cell lung cancer","volume":"15","author":"Lau","year":"2023","journal-title":"Cancers"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.21037\/gs-24-400","article-title":"Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer","volume":"13","author":"Zhao","year":"2024","journal-title":"Gland Surg"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41392-024-01826-z","article-title":"Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities","volume":"9","author":"Yin","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12964-025-02270-4","article-title":"Nanobodies and their derivatives: pioneering the future of cancer immunotherapy","volume":"23","author":"Li","year":"2025","journal-title":"Cell Commun Signal"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood.2024025277","article-title":"Bivalent CD47 immunotoxin for targeted therapy of T-cell acute lymphoblastic leukemia","volume":"145","author":"Ma","year":"2025","journal-title":"Blood"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"e2004240","DOI":"10.1002\/smll.202004240","article-title":"Nanoparticle-enabled dual modulation of phagocytic signals to improve macrophage-mediated cancer immunotherapy","volume":"16","author":"Zhang","year":"2020","journal-title":"Small"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"121790","DOI":"10.1016\/j.lfs.2023.121790","article-title":"PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors","volume":"326","author":"Liu","year":"2023","journal-title":"Life Sci"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"188771","DOI":"10.1016\/j.bbcan.2022.188771","article-title":"CD47: beyond an immune checkpoint in cancer treatment","volume":"1877","author":"Bian","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41421-024-00703-x","article-title":"Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer","volume":"10","author":"Jin","year":"2024","journal-title":"Cell Discov"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/2159-8290.CD-23-1300","article-title":"Spatially segregated macrophage populations predict distinct outcomes in colon cancer","volume":"14","author":"Matusiak","year":"2024","journal-title":"Cancer Discov"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/s41467-024-46220-z","article-title":"Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphoma","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s44276-024-00056-8","article-title":"New insights into macrophage polarization and its prognostic role in patients with colorectal cancer liver metastasis","volume":"2","author":"Khanduri","year":"2024","journal-title":"BJC Rep"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","article-title":"Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","article-title":"Glioblastoma at the crossroads: current understanding and future therapeutic horizons","volume":"10","author":"Singh","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"101099","DOI":"10.1016\/j.jpha.2024.101099","article-title":"Therapeutic strategies targeting CD47-SIRPalpha signaling pathway in gastrointestinal cancers treatment","volume":"15","author":"Che","year":"2025","journal-title":"J Pharm Anal"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"116898","DOI":"10.1016\/j.bcp.2025.116898","article-title":"Dual blockade of GSTK1 and CD47 improves macrophage-mediated phagocytosis on cancer cells","volume":"236","author":"Yu","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3390\/cells14100741","article-title":"Tumor-associated macrophages: polarization, immunoregulation, and immunotherapy","volume":"14","author":"Saeed","year":"2025","journal-title":"Cells"},{"key":"ref59","first-page":"2395","article-title":"Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities","volume":"379","author":"Yang","year":"2025","journal-title":"Drug Deliv Transl Res"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1342647","DOI":"10.3389\/fimmu.2024.1342647","article-title":"STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"e010760","DOI":"10.1136\/jitc-2024-010760","article-title":"A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy","volume":"13","author":"Marron","year":"2025","journal-title":"J Immunother Cancer"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"e011170","DOI":"10.1136\/jitc-2024-011170","article-title":"Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial","volume":"13","author":"Luke","year":"2025","journal-title":"J Immunother Cancer"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","article-title":"Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy","volume":"44","author":"Imani","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"104982","DOI":"10.1016\/j.yexmp.2025.104982","article-title":"Revisiting TAM polarization: beyond M1- and M2-type TAM toward clinical precision in macrophage-targeted therapy","volume":"143","author":"Wang","year":"2025","journal-title":"Exp Mol Pathol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"e2414425","DOI":"10.1001\/jamanetworkopen.2024.14425","article-title":"Patient-reported outcomes in phase 3 clinical trials for blood cancers: a systematic review","volume":"7","author":"Patel","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-11\/OncolRes-33-11-71708\/OncolRes-33-71708.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:23:51Z","timestamp":1763346231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n11\/64082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":65,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2025.071708","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}